论文部分内容阅读
流行性乙型脑炎简称乙脑,是我国夏、秋两季流行的主要传染病之一,除新疆、西藏、青海外,全国各地均有病例发生。我国每年的发病人数约为2.5万,病死率约占10%,有大约15%的患者留下不同程度的后遗症。乙脑致死、致残率高,乙脑疫苗在一定程度上减少了乙脑的发病率,但对于已经发病的患者,目前世界上仍没有针对性的特效药物或治疗手段。日前,中国科学院武汉病毒研究所的肖庚富课题组通过对美国食品药品监督管理局批准的1018种药物进行筛选,得到了5种对乙脑的治疗指数大于10的小分
JE, abbreviated as JE, is one of the major infectious diseases epidemic in summer and autumn of China. Except Xinjiang, Tibet and Qinghai, cases have occurred in all parts of the country. The annual incidence in China is about 25,000, and the case fatality rate is about 10%. About 15% of the patients left varying degrees of sequelae. Japanese encephalitis caused by death and high disability, Japanese encephalitis vaccine to reduce the incidence of Japanese encephalitis to a certain extent, but for patients who have been in the disease, there is no specific drug or treatment in the world. Recently, the Xiao-Geng-Fu Task Force of the Wuhan Institute of Virology, Chinese Academy of Sciences, screened 1018 drugs approved by the U.S. Food and Drug Administration and obtained five subtypes with a therapeutic index greater than 10 for JE